Deborah Dunsire, president and CEO of multinational pharmaceutical company Lundbeck A/S, expects more business opportunities to unfold rapidly in China, the second-largest market for the company.
"As the government focuses on expanding healthcare and introducing more primary care in rural areas, and access to innovation, we feel we are a great fit for China," she said.
A world player in psychiatric and neurological disorders, the Copenhagen-headquartered company launched its first drug in the China market through cooperation with local partners in the late 1990s, for the treatment of mild to moderate depression and anxiety.
Since then, Lundbeck has launched a series of novel drugs in China for a myriad of diseases such as depression, Alzheimer's disease, Parkinson's disease, and major depressive disorders. It founded a China branch in 2007. About one in four patients with depression in China is treated with a Lundbeck branded medication, and the China market is growing rapidly for the company, although it is still significantly smaller than the US market.
During her recent visit to Beijing, China Daily talked to the pharmaceutical company's new female leader about the China market, and how she views the Chinese economy, globalization and female leadership.
(Source: China Daily)
No comments:
Post a Comment